'Tis the season for burying the hatchet. A settlement last month by R2 and iCAD over patent infringement was followed Sept. 19 by the announcement that Nomos and Zmed had settled their differences. The radiotherapy companies put to rest two pending
'Tis the season for burying the hatchet. A settlement last month by R2 and iCAD over patent infringement was followed Sept. 19 by the announcement that Nomos and Zmed had settled their differences. The radiotherapy companies put to rest two pending patent infringement suits relating to patient positioning and target verification products, namely Nomos BAT and BAT SXi products and Zmed's SonArray product. The agreement resolves all claims and provides cross-licensing of patent rights.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.